This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Paul Nioi, PhD
Vice President, Discovery and Translational Research at Alnylam Pharmaceuticals

Profile

Dr. Paul Nioi, PhD, joined Alnylam in March 2018 and leads both the human genetics and translational research functions. Building upon his depth of prior experience, he has led the creation of the Alnylam Translational Genetics Center (ATGC), putting in place a capability that allows the deep mining of genotype-phenotype databases representing hundreds of thousands of individuals. Paul’s team applies these data to identify new drug targets and to gain important insights into disease trajectories to aid patient discovery efforts. His group is also responsible for advancing new liver and CNS RNAi therapeutics for a variety of diseases.

Alnylam has pioneered the translation of RNA interference from a Nobel Prize-winning discovery into a new class of approved medicines.

Prior to Alnylam, Paul spent 15 years in the biotech and pharmaceutical industries, including tenures at deCODE genetics, Amgen, and Schering-Plough.

Paul obtained his academic training at the University of Edinburgh (BSc) and the University of Dundee (PhD).